Drug insight: Cyclo-oxygenase 2 inhibitors and cardiovascular risk - Where are we now?

Nature Clinical Practice Cardiovascular Medicine

Volumn 2, Issue 6, 2005, Pages 290-300

  Spektor, Gary ^a   Fuster, Valentin ^a  

^a MOUNT SINAI MEDICAL CENTER   (United States)

Author keywords

Cardiovascular risk; Cardiovascular thrombosis; COX2 inhibitors; Coxibs

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DICLOFENAC; ETORICOXIB; HEPARIN; IBUPROFEN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LUMIRACOXIB; MELOXICAM; NABUMETONE; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PLACEBO; PROSTACYCLIN; ROFECOXIB; THROMBOXANE A2; VALDECOXIB;

ARTHRITIS; CARDIOTOXICITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DOSE RESPONSE; DRUG MECHANISM; DRUG SAFETY; DRUG SELECTIVITY; GASTROINTESTINAL TOXICITY; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; LOW DRUG DOSE; LUNG EMBOLISM; META ANALYSIS; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; SIDE EFFECT; STROKE; SUDDEN DEATH; SYSTEMATIC REVIEW; THROMBOSIS; UNSTABLE ANGINA PECTORIS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CARDIOVASCULAR DISEASES; CORONARY THROMBOSIS; CYCLOOXYGENASE 2 INHIBITORS; GASTROINTESTINAL TRACT; HUMANS; INFLAMMATION; RISK ASSESSMENT; RISK FACTORS;

EID: 20744457410     PISSN: 17434297     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncpcardio0214     Document Type: Review

References (59)

1. Sanmuganathan PS et al. (2001) Aspirin for primary prevention of coronary heart disease: safety and absolute benefit related to coronary risk derived from meta-analysis of randomised trials. Heart 85: 265-271
2. US Preventive Services Task Force (2002) Aspirin for the primary prevention of cardiovascular events: recommendations and rationale. Ann Intern Med 136: 157-160
3. Antiplatelet Trialists' Collaboration (1994) Collaborative overview of randomized trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 308: 81-106
4. Ryan TJ et al. (1999) 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 34: 890-911
5. Brooks PM and Day RO (1991) Nonsteroidal anti-inflammatory drugs - differences and similarities. N Engl J Med 324: 1716-1725
6. IMS Health Inc. (online 26 April 2002) IMS reports 16.9 percent growth in 2001 U.S. prescription sales. [http://www.imshealth.com/ims/portal/front/articleC/ 0,2777,6025_3665_1003965,00.html] (Accessed 22 April 2005)
7. Vane JR and Botting RM (1998) Mechanism of action of nonsteroidal anti-inflammatory drugs. Am J Med 104 (Suppl 3A): 2S-8S
8. Kam PC and See AU (2000) Cyclo-oxygenase isoenzymes: physiological and pharmacological role. Anaesthesia 55: 442-449
9. Whittle BJ et al. (1980) Selective inhibition of prostaglandin production in inflammatory exudates and gastric mucosa. Nature 284: 271-273
10. Cryer B and Feldman M (1998) Cyclooxygenase-1 and cyclooxygenase-2 selectivity of widely used nonsteroidal anti-inflammatory drugs. Am J Med 104: 413-421
11. Reilly IA and Fitzgerald GA (1987) Inhibition of thromboxane formation in vivo and ex vivo: Implications for therapy with platelet inhibitory drugs. Blood 69: 180-186
12. Patrono C et al. (1985) Clinical pharmacology of platelet cyclooxygenase inhibition. Circulation 72: 1177-1184
13. FitzGerald GA (2002) Cardiovascular pharmacology of nonselective nonsteroidal anti-inflammatory drugs and coxibs: clinical considerations. Am J Cardiol 89: 26D-32D
14. Catella-Lawson F and Crofford LJ (2001) Cyclooxygenase inhibition and thrombogenicity. Am J Med 110 (Suppl 3A): 28S-32S
15. Mukherjee D (2002) Selective cyclooxygenase-2 (COX-2) inhibitors and potential risk of cardiovascular events. Biochem Pharmacol 63: 817-821
16. Linton MF and Fazio S (2004) Cyclooxygenase-2 and inflammation in atherosclerosis. Curr Opin Pharmacol 4: 116-123
17. Weir MR et al. (2003) Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program. Am Heart J 146: 591-604
18. Meagher EA et al. (2003) Balancing gastroprotection and cardioprotection with selective cyclooxygenase-2 inhibitors: clinical implications. Drug Saf 26: 913-924
19. McAdam BF et al. (1999) Systemic biosynthesis of prostacyclin by cyclooxygenase (COX)-2: the human pharmacology of a selective inhibitor of COX-2. Proc Natl Acad Sci U S A 96: 272-277
20. Yamamoto T et al. (2001) Effect of cyclooxygenase-2 inhibitor (celecoxib) on the infarcted heart in situ. Pharmacology 63: 28-33
21. Bing RJ and Lomnicka M (2002) Why do cyclooxygenase-2 inhibitors cause cardiovascular events? J Am Coll Cardiol 39: 521-522
22. Aw TJ et al. (2005) Meta-analysis of cyclooxygenase-2 inhibitors and their effects on blood pressure. Arch Intern Med 165: 490-496
23. Topper JN et al. (1996) Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: Cyclooxygenase-2, manganese superoxide dismutase and endothelial cell nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci USA 93: 10417-10422
24. Shinmura K et al. (2000) Cyclooxygenase-2 mediates the cardioprotective effects of the late phase of ischemic preconditioning in conscious rabbits. Proc Natl Acad Sci USA 97: 10197-10202
25. Bolli R et al. (2002) Discovery of a new function of cyclooxygenase (COX)-2: Cox-2 is a cardioprotective protein that alleviates ischemia/reperfusion injury and mediates the late phase of preconditioning. Cardiovasc Res 55: 506-519
26. Hennan JK et al. (2001) Effects of selective cyclooxygenase-2 inhibition on vascular responses and thrombosis in canine coronary arteries. Circulation 104: 820-825
27. Dowd NP et al. (2001) Inhibition of cyclooxygenase-2 aggravates doxorubicin-mediated cardiac injury in vivo. J Clin Invest 108: 585-590
28. Cheng Y et al. (2002) Role of prostacyclin in the cardiovascular response to thromboxane A2. Science 296: 539-541
29. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528
30. Solomon DH et al. (2002) Nonsteroidal anti-inflammatory drug use and acute myocardial infarction. Arch Intern Med 162: 1099-1104
31. Watson DJ et al. (2002) Lower risk of thromboembolic cardiovascular events with naproxen among patients with rheumatoid arthritis. Arch Intern Med 162: 1105-1110
32. Rahme E et al. (2002) Association between naproxen use and protection against acute myocardial infarction. Arch Intern Med 162: 1111-1115
33. Ray WA et al. (2002) Non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease: an observational cohort study. Lancet 359: 118-123
34. Graham DJ et al. (2005) Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study. Lancet 365: 475-481
35. Silverstein FE et al. (2000) Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis. The CLASS study: a randomized controlled trial. Celecoxib Long-term Arthritis Safety Study. JAMA 284: 1247-1255
36. Catella-Lawson F et al. (2001) Cyclooxygenase inhibitors and the antiplatelet effects of aspirin. N Engl J Med 345: 1809-1817
37. Nussmeier NA et al. (2005) Complications of the COX-2 inhibitors parecoxib and valdecoxib after cardiac surgery. N Engl J Med 352: 1081-1091
38. Whelton A (online 7 March 2005) Safety of parecoxib and valdecoxib in the treatment of postoperative pain following coronary artery bypass graft surgery or major general surgery [http://www.acc05online.acc.org/highlights/ keyLectures.aspx?sessionId=8030&&date=7] (accessed 22 April 2005)
39. Matsumoto AK et al. (2002) A randomized controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis. J Rheumatol 29: 1623-1630
40. Farkouh ME et al. (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364: 675-684
41. Mukherjee D et al. (2001) Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA 286: 954-959
42. Reicin AS et al. (2002) Comparison of cardiovascular thrombotic events in patients with osteoarthritis treated with rofecoxib versus nonselective nonsteroidal anti-inflamamtory drugs (ibuprofen, diclofenac, and nabumetone). Am J Cardiol 89: 204-209
43. Konstam MA et al. (2001) Cardiovascular thrombotic events in controlled clinical trials of rofecoxib. Circulation 104: 2280-2288
44. White WB et al. (2003) Cardiovascular thrombotic events in arthritis trials of the cyclooxygenase-2 inhibitor celecoxib. Am J Cardiol 92: 411-418
45. White WB et al. (2004) Effects of the cyclooxygenase-2 specific inhibitor valdecoxib versus nonsteroidal anti-inflammatory agents and placebo on cardiovascular thrombotic events in patients with arthritis. Am J Ther 11: 244-250
46. Mamdani M et al. (2003) Effect of selective cyclooxygenase-2 inhibitors and naproxen on short-term risk of acute myocardial infarction in the elderly. Arch Intern Med 163: 481-486
47. Solomon DH et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068-2073
48. Shaya FT et al. (2005) Selective cyclooxygenase-2 inhibition and cardiovascular effects: an observational study of a Medicaid population. Arch Intern Med 165: 181-186
49. Bresalier RS et al. (2005) Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. N Engl J Med 352: 1092-1102
50. Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. Ademona Prevention with Celecoxib (APC) Study Investigators. N Engl J Med 352: 1071-1080
51. Levin B (Online 18 April 2005) The PreSAP Trial (Prevention of Colorectal Sporadic Adenomatous Polyps). [http://www.masterdocs.com/PDF/C7%20The%20PreSAP%20Trial%20(Prevention%20 of%20Colorectal%20Sporadic%20Adenomatous%20Polyps)%20-%20 Bernard%20Levin%20MD.pdf] (accessed 22 April 2005)
52. NIH Department of Health and Human Services, NIH News (online 20 December 2004) Use of non-steroidal anti-inflammatory drugs suspended in large Alzheimer's disease prevention trial [http://www.nih.gov/news/pr/dec2004/od-20.htm] (accessed 22 April 2005)
53. Konstam MA and Weir MR (2002) Current perspective on the cardiovascular effects of coxibs. Cleve Clin J Med 69 (Suppl 1): S147-S152
54. Altman R et al. (2002) Efficacy assessment of meloxicam, a preferential cyclooxygenase-2 inhibitor, in acute coronary syndromes without ST-segment elevation: the Nonsteroidal Anti-inflammatory Drugs in Unstable Angina Treatment-2 (NUT-2) pilot study. Circulation 106: 191-195
55. Chenevard R et al. (2003) Selective COX-2 inhibition improves endothelial function in coronary artery disease. Circulation 107: 405-409
56. Van Hecken A et al. (2000) Comparative inhibitory activity of rofecoxib, meloxicam, diclofenac, ibuprofen and naproxen on COX-2 versus COX-1 in healthy volunteers. J Clin Pharmacol 40: 1109-1120
57. Dalen JE (2002) Selective COX-2 inhibitors, NSAIDs, aspirin and myocardial infarction. Arch Intern Med 162: 1091-1092
58. Jenkins JK (online 6 April 2005) Memorandum: Analysis and recommendations for Agency action regarding non-steroidal anti-inflammatory drugs and cardiovascular risk. [http://www.fda.gov/cder/drug/infopage/cox2/NSAIDdecisionMemo.pdf] (accessed 22 April 2005)
59. Abramson SB et al. (2001) Controversies in COX-2 inhibitor therapy: closing remarks. Clin Exp Rheumatol 19 (Suppl 25): S77-S8O